# Phase I/II Study of PDR001 in Patients With Advanced Malignancies

> **NCT02404441** · PHASE1,PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 319 (actual)

## Conditions studied

- Melanoma
- Non-small Sell Lung Cancer (NSCLC)
- Triple Negative Breast Cancer
- Anaplastic Thyroid Cancer
- Other Solid Tumors

## Interventions

- **BIOLOGICAL:** PDR001

## Key facts

- **NCT ID:** NCT02404441
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-04-27
- **Primary completion:** 2020-07-21
- **Final completion:** 2020-07-21
- **Target enrollment:** 319 (ACTUAL)
- **Last updated:** 2022-08-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02404441

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02404441, "Phase I/II Study of PDR001 in Patients With Advanced Malignancies". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02404441. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*